Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience.

MLA

Rupp, Martin, et al. “Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience.” Current Oncology (Toronto, Ont.), vol. 30, no. 7, July 2023, pp. 6559–74. EBSCOhost, https://doi.org/10.3390/curroncol30070481.

APA

Rupp, M., Fanton-Aita, F., Snow, S., Wheatley-Price, P., Melosky, B., Juergens, R. A., Chu, Q., Blais, N., Banerji, S., Ng, R., Khoudigian, S., Sharma, A., On, P. V., & Liu, G. (2023). Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience. Current Oncology (Toronto, Ont.), 30(7), 6559–6574. https://doi.org/10.3390/curroncol30070481

Chicago

Rupp, Martin, Fiorella Fanton-Aita, Stephanie Snow, Paul Wheatley-Price, Barbara Melosky, Rosalyn A Juergens, Quincy Chu, et al. 2023. “Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience.” Current Oncology (Toronto, Ont.) 30 (7): 6559–74. doi:10.3390/curroncol30070481.